Ask AI
Navigating the CKM axis module 2

CE / CME

Navigating the CKM Axis: Improving CKD and HF Outcomes With Novel and Emerging GMDT

European Learners: 0.50 EBAC® CE Credit

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Released: December 19, 2025

Expiration: December 18, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

A 72-year-old woman with heart failure with mildly reduced ejection fraction (HFmrEF; left ventricular ejection fraction 45%), type 2 diabetes (T2D), and chronic kidney disease (CKD) stage 3b/A3 is being considered for intensification of therapy to improve heart and kidney outcomes. The patient is on lisinopril and loop diuretics. Her BMI is 32 kg/m2, blood pressure is 128/78 mm Hg, serum potassium is 4.7 mmol/L, estimated glomerular filtration rate (eGFR) is 35 mL/min/1.73 m², urine–albumin-to-creatinine ratio (UACR) is 450 mg/g, and A1C is 7.1%. According to current heart failure (HF) and CKD guidelines, which combination would optimize cardiovascular–kidney–metabolic (CKM) outcomes while minimizing adverse effects at this time?

2.

In a randomized, dose‑finding phase II trial of vicadrostat in patients with CKD on stable RAAS inhibitor therapy, what key result was observed regarding albuminuria?